CR Pharma was among the investors in a $45.8m round that pushed the gene therapy developer's funding to about $170m in the past 14 months.
US-headquartered genomic drug developer Denovo Biopharma has completed a series D round featuring a fund operated by pharmaceutical producer CR Pharma, at almost RMB300m ($45.8m), DealStreetAsia reported yesterday.
CICC Capital’s CICC Qide fund co-led the round with Yingke PE, according to a WeChat post cited by DealStreetAsia. It included Silicon Paradise Asset Management Group, Fang Fund Partners, Sangel Capital, Hosencare Brothers and Zheshang Industrial Integration Asset Management.
Denovo is developing gene therapies for cancer and central nervous system disorders, and…
